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ABSTRACT

The therapeutic value of biologics is of extreme importance in the treatment of most major
cancers. Biologics account for half of the oncologic pharmacology market. As the population of
the United States ages, the demand for biologics is expected to increase. The future supply of
biologics may be prohibited by cost. Biosimilar biologics are highly similar to existing Food and
Drug Administration-licensed biologics and have the potential to meet biological demand.
Market introduction of biosimilars at a lower cost than reference biologics creates an opportunity
for reducing the nation’s financial burden. Despite the obvious gains from biosimilar use,
adoption into clinical practice continues to lag. Numerous factors, including a lack of education
on the part of prescribers, continue to hinder the widespread adoption of biosimilars into
practice. The purpose of this integrative review is to examine the evidence surrounding
biosimilar determination and ascertain if adult patients diagnosed with cancer can be treated with
biosimilars as compared to reference biologics without a compromise in safety and efficacy
throughout the course of therapy.
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FEASIBILITY OF BIOSIMILAR INTEGRATION IN ONCOLOGY PRACTICE
Oncology practice is highly dependent on the use of biologics, which account for half of
the oncologic pharmacology market (Konstantinidou, 2020). As the population ages and cancer
prevalence increases, the demand for life-saving biologic therapeutics is expected to increase.
Notably, access to biologics may be prohibited by cost. Biosimilar biologics are highly similar to
existing Food and Drug Administration (FDA)-licensed biologics (reference biologics) with no
clinically meaningful differences in safety, purity, or potency as compared to reference products
(FDA, 2015). Biosimilars are not generics, but like generic drugs, biosimilars are approved by an
abbreviated regulatory pathway and are less expensive than reference products. Table 1 outlines
the differences between biosimilars and generic drugs.
Biosimilar uptake is expected to provide cost-savings for patients, healthcare systems,
and the nation. Cost-savings will improve patient access to life-saving biologic therapeutics
with a resultant improvement in patient outcomes. By 2024, patents on eight major oncology
biologics will expire (Pittman, et al., 2019). As patents for currently licensed reference
biologics expire, the number of FDA-approved biosimilars is expected to increase. As of
December 2020, 29 biosimilars have been approved by the FDA, many for use in the oncology
setting (see Table 2) (FDA, 2020). Despite the potential for reducing the financial burden on the
nation’s healthcare system, the availability of oncologic biosimilars has not been associated
with the uniform adoption of biosimilars into clinical practice.
Clinical uptake of biosimilars has been hindered by confusion surrounding the
abbreviated approval process for biosimilars. A demonstration of biosimilarity is dependent on
comparative analytical data as opposed to the safety and efficiency data required for approval of
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a reference biologic (FDA, 2015). This difference is poorly understood by oncology providers
and limits the comfortable prescribing of biosimilars (Cook et al., 2019). Other factors that limit
biosimilar utilization include immunogenicity concerns, issues related to the process of
extrapolation, interchangeability, third-party reimbursement, and pricing. Patients may harbor
concerns about safety and efficiency as well. Therefore, this integrative review (IR) will examine
the empirical evidence surrounding oncology biosimilars to determine if the widespread adoption
of biosimilars in clinical practice is feasible.
Defining Concepts and Variables
A biosimilar is a biological medicine that has highly similar properties to an already
approved FDA biologic without any clinically meaningful differences in terms of the safety,
purity, or potency of the product (FDA, 2017). The model for demonstrating biosimilarity can be
framed from a stepwise approach. Key concepts in demonstrating biosimilarity include
preclinical analytical comparability, demonstrating analytical similarity, non-clinical
pharmacokinetic (PK)/pharmacodynamic (PD) toxicology assessments, human PK/PD
toxicology assessments, and a phase III clinical assessment of biosimilar safety, efficacy, and
immunogenicity (Markus et al., 2017).
Rationale for Conducting the Review
As the population ages, a significant rise in the number of cancer cases is expected. In
2021, the number of new cancer cases in the United States (US) is expected to approximate
1,898,160, or 5200 new cases per day (Siegel et al., 2021). A demand for efficacious oncology
therapeutics will accompany the increase in cancer incidence. Advances in science, technology,
and genomics make precision treatment possible and result in improved patient outcomes.
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Biologic drugs play an important role in the precise treatment of malignancy, and the demand for
access to life-saving biologic therapeutics is high and expected to increase.
Biologics were first approved for use in cancer treatment and supportive care in 1989.
They are produced in living systems and purified in complex, multi-step processes, including
recombinant DNA technology and controlled gene expression. Biologics are molecularly
complex, difficult to characterize, and subject to changes in manufacturing conditions. Biologic
proteins can be 1000 times larger than chemically synthesized, small-molecule drugs (Patel et al.,
2018). The structural complexity of biologics is further defined by the primary, secondary,
tertiary, and in some cases, the quaternary structure of the protein (Vulto & Jaquez, 2017). It is
this complexity that makes it difficult to identically reproduce biologics.
Biologics are subject to post-translational modifications (PTMs) such as glycosylation,
oxidation, phosphorylation, sulphation, lipidation, disulphide bond formation, and deamidation.
These PTMs have the potential to impact the immunogenicity of biologics, thus creating
concerns about biologic safety and efficacy (Declerck et al., 2016). PTMs can occur naturally or
be introduced by the manufacturing process. The manufacturing process for biologics is
challenging and batch-to-batch variability is the norm. This typically does not compromise the
physical, chemical, biological, or microbiological properties that define biologics (Vulto &
Jaquez, 2017). These properties are referred to as the critical quality attributes of the product.
Biologic approval begins with a biologic license application and is regulated under 21
CFR 600-680. Approval requires at least three phases of safety and efficacy trials for every
indication in which licensure is sought (FDA, 2015). The complexity of biologic development
and manufacturing is costly. Estimates for the costs of manufacturing a biologic are between $95
and $225 per gram (Roy, 2019). The demand for such innovation is logical, but availability may
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be prohibited by cost. US expenditures for oncology medicines are largely driven by biologics
and reached nearly $150 billion in 2018, a 12.9% increase from the previous year (IQVIA,
2019). Monoclonal antibodies alone account for 35% of US drug expenditures (Patel, 2018). The
continued delivery of biologically based cancer treatment must be balanced against the economic
limitations of the US healthcare system.
The Biologics Price Competition and Innovation Act of 2009 (BPCI Act) was enacted as
part of the Affordable Care Act on March 23, 2010, as a national response to the real and
anticipated economic burden created by the demand for and use of biologics. The act is
predicated on the fact that patents for existing licensed reference biologics have or will expire.
By 2023, the patents of approximately 20 biologics will expire (Konstantinidou et al., 2020). Just
as the Drug Price Competition and Patent Restoration Act created an approval pathway for small
molecule generic entrants and promoted competition between brand and generic manufacturers,
the BPCI Act created an abbreviated licensure pathway (351(k)) for biological products shown to
be biosimilar to or interchangeable with an FDA-licensed biological reference product in which
the patent has expired (FDA, 2015). When the BPCI Act was passed, it was projected that the
introduction of biosimilars at 20% to 30% lower costs would create competition among
manufacturers of biologics, drive down biologics’ cost, and improve patient access to needed
biologic therapies (Nabhan et al., 2018).
The abbreviated approval process outlined by the BPCI Act focuses on criteria for
demonstrating a high degree of similarity to a reference biologic and differs from traditional
biologic endpoints. The establishment of biosimilarity involves an extensive characterization of
the physiochemical and biological attributes of the biosimilar as compared to the reference
biologic. Determining biosimilarity does not follow traditional new drug development but
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depends on knowledge gained from an understanding of the reference product. The FDA
recommends a stepwise approach including in vitro analytical testing, nonclinical comparative
pharmacology testing, a toxicology assessment, PK/PD testing, and one or more clinical
comparative studies to confirm the quality, safety, and efficacy of the product (Markus et al.,
2017).
Demonstrating biosimilarity involves an assessment of clinical immunogenicity. The goal
of an immunogenicity assessment is to uncover potential differences in human immune
responses between the biosimilar and the reference biologic. Clinical comparative studies can
address any residual uncertainty surrounding the biosimilar. Approval of a biosimilar means that
“the biological product is highly similar to the reference product notwithstanding minor
differences in clinically inactive components,” and that “there are no clinically meaningful
differences between the biological product and the reference product in terms of the safety,
purity, and potency of the product” (FDA, 2015, p. 24).
As of December 2020, 29 biosimilars have been approved by the FDA for use, many in
the oncology setting (see Table 2) (FDA, 2020). Biosimilars can provide significant savings for
healthcare systems. It is predicted that the uptake of biosimilars will save the US $250 billion
between 2014 and 2024 (Leber, 2018). Much of the enthusiasm and anticipated savings come
from an examination of the European biosimilar market, where biosimilars were introduced in
2006 and have resulted in significant healthcare cost savings. Biologic savings depend on an
uptake of biosimilars. Unlike Europe, where biosimilar uptake has been embraced, uptake in the
US has moved at a slower pace. The low utilization of biosimilars prohibits the achievement of
the policymakers’ goals of increasing competition, driving down prices, and improving patient
access to biologics.
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Factors contributing to the delayed uptake of biosimilars in the US include ongoing
patent litigation and rebate schemes (Leber, 2018). A key reason for the delayed adoption of
biosimilars into clinical practice and clinical guidelines is provider resistance, largely driven by a
lack of provider knowledge and a need for education about the approval process, safety profiles,
extrapolation, and interchangeability. A survey by Cook et al. (2019) among 77 oncology
clinicians found that understanding of biosimilars is low, and educational needs are high.
Provider fears also hinder the use of biosimilars. A commonly cited concern is the lack of
traditional safety and efficacy data generated by clinical trials and real-world data. Other
concerns include the potential for immunogenicity, misgivings about extrapolation, and a
perceived loss of control if biosimilars become interchangeable (Pittman, 2019). Providing
education and addressing provider fears is an important step in increasing the use of biosimilars.
In fact, clinicians indicated a 40% increase in the likelihood of prescribing a biosimilar given
adequate data on biosimilar safety and efficacy (Cook et al., 2019). Alleviating provider fears
will require an understanding of biosimilar determination and a review of the evidence
supporting the incorporation of biosimilars into routine clinical practice.
Purpose and/or Review Question
Biologics play an important role in the treatment of malignancy. An aging population and
an increase in the number of newly diagnosed cancers are accompanied by an increase in the
demand for life-saving biologics. Biologics are expensive and create a chronic burden for the US
healthcare system. Guaranteed access to therapeutic biologics is threatened by a lack of cost
containment. Biosimilars are biologics that are highly similar to FDA approved reference
biologics. As a result of the approval process, biosimilars are introduced at a lower cost than
reference biologics with resultant savings to healthcare stakeholders and improved patient access
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to biologics. Despite availability, the uptake of biosimilars into clinical practice is suboptimal. A
lack of awareness among oncology providers concerning evidence for the safe incorporation of
biosimilars into clinical practice limits biosimilar utilization. If continued, the lack of utilization
will result in forfeiture of the biosimilar space and the loss of billions in healthcare savings.
The purpose of this IR is to examine the evidence surrounding the biosimilar
determination of available oncology therapeutics. This review should help determine if the
adoption of biosimilars to formulary and into clinical practice is feasible without a compromise
in safety or efficacy as compared to reference products. This IR addresses the following clinical
question: can adult patients diagnosed with cancer be treated with biosimilars as compared to
reference biologics without a compromise in safety and efficacy over the course of therapy?
Inclusion and Exclusion Criteria
This review primarily focuses on quantitative evidence as it relates to demonstrating
biosimilarity. Inclusion criteria include systematic reviews, meta-analyses, and randomized
controlled trials (RCTs). The adult age range is applied. Outcomes of interest include supportive
care and therapeutic oncology biosimilars. Non-English studies and those failing to report
comparative outcomes are excluded.
Conceptual Framework
The framework for this IR is supported by the methodology of Whittemore and Knafl
(2005). The methodology allows for the inclusion of experimental and non-experimental
research. This review is based on experimental research. The initial stage of any review is
problem identification. This review addresses the safe incorporation of biosimilars into oncology
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practice. Problem identification is followed by a literature search, data synthesis, and data
presentation. This review follows these steps in accordance with the proposed methodology.
COMPREHENSIVE AND SYSTEMATIC SEARCH
Search Organization and Reporting Strategies
The library staff at Liberty University was consulted prior to the initiation of the literature
review. In this IR, the literature review was conducted in accordance with the methodology
proposed by Whittemore and Knafl (2005). Whittemore and Knafl (2005) recommend that the
literature search for an IR be clearly documented and include search terms, databases used, and
the inclusion and exclusion criteria for determining relevant primary sources. Whittemore and
Knafl (2005) point out that a gold standard for evaluating and interpreting literature quality does
not exist. This IR uses levels of the evidence outlined by Melnyk and Fineout-Overholt (2015)
for critical appraisal of the literature.
Terminology
A systematic search was conducted using several databases. The CINAHL database,
maintained by the EBSCO host platform, was selected due to its comprehensive index of nursing
research and information and access to peer-reviewed journals. The Cochrane Library database,
operated by the CRD, EBSCO, OVID, and Wiley platforms, allowed for a search of systematic
reviews. Medline (Proquest) was selected because this database includes the platforms of
PubMed and the Web of Science. The Nursing & Allied Health Database provided indexed
journal content from the nursing literature and other related disciplines using the Proquest
platform. Additionally, Clinicaltrials.gov was selected as a privately and publicly funded
database of clinical studies conducted from around the world. Assistance to full-text articles and
search assistance was provided by the research department of Liberty University.
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MANAGING THE COLLECTED DATA
For this IR, the keywords used to conduct a comprehensive search of the databases were
“biosimilars” and “oncology.” Inclusion criteria were: (a) scholarly works published in a peerreviewed journal, (b) works written in English, (c) works published within the last five years, and
(d) quantitative studies consisting of systematic reviews, meta-analyses, RCTs. Exclusion
criteria were: (a) qualitative studies, (b) opinion articles, and (c) articles published before
January 1, 2015.
The initial search resulted in a sample of 193 articles. The CINAHL search was conducted
using the Boolean/Phrase function for the selected keywords, and 90 studies were identified. An
advanced search within the Cochrane Library found five articles. Medline (ProQuest) was
searched using the advanced function and the qualifying peer-review box. Forty-two studies
were isolated. The Nursing & Allied Health database search was conducted in the advanced
mode with the selection of the peer-reviewed function, and 50 articles were identified. A search
of the Clinicaltrials.gov website using the advanced mode and application of filters for
oncology, biosimilars, and interventional studies produced six studies for review.
QUALITY APPRAISAL
The final sample for this IR was selected after the application of inclusion and exclusion
criteria. Twenty-seven studies remained. Once duplicates were removed, 20 studies were
available for review. Twenty remaining articles were assessed for levels of evidence, sources of
bias, and the extent to which an FDA-approved endpoint was measured in determining
biosimilarity. Articles were also graded for relevance on a two-point scale (high or low). Fifteen
studies remained for inclusion in this IR (see Appendix A). The appraisal tool for the studies will
be reviewed below.
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Sources of Bias
Identifying bias starts by examining each study for potential sources of bias. The focus on
bias provides internal validity (Remington, 2020). Fifteen studies included in this IR were
examined for potential bias by examining the selection of participants, quality of measurements,
rate of attrition, and symmetry of performance. Study limitations are outlined in Appendix A.
Overall, some bias may be present across studies due to small sample size, varying outcome
measures, and statistical underpowering. Bias may also occur due to the selection of only highlevel evidence.
Internal Validity
Internal validity occurs when the results of the study approximate the truth (Remington,
2020). The validity of the systematic reviews and meta-analyses was determined by assessing the
comprehensiveness of included sources and the degree to which each source was appraised. The
internal validity of RCTs was considered good if the trials outlined adequate randomization,
comparison groups, measurement criteria with instrument validity, and outcomes. Bias, as
outlined above, was also considered.
Appraisal Tool
A gold standard for evaluating and interpreting literature quality does not exist
(Whittemore & Knafl, 2005). Nonetheless, any evidence included in an IR should be critically
evaluated (Remington, 2020). This IR uses levels of the evidence outlined by Melnyk and
Fineout-Overholt (2015) for critical appraisal of the literature. Levels range from I-VII. Level I
evidence is supported by systematic reviews or meta-analyses of RCTs or evidence-based
clinical practice guidelines based on systematic reviews. Level II evidence comes from a welldesigned RCT. Level III depends on a controlled trial without randomization (quasi-experimental
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study). Level IV requires a single nonexperimental study (case-control, correlational, or cohort
study). Level V is based on a systematic review of descriptive and qualitative studies. Level VI
involves a single descriptive or qualitative study. Level VII entails an opinion of authorities
and/or reports of expert committees.
Applicability of Results
The applicability of the studies included in the IR was assessed using the appraisal tool
described above. Each study has been appraised with results highlighted in the appraisal matrix
(see Appendix A). Categories included in the matrix to help support the credibility of the data
analysis, and findings are as follows: identifying article information, study purpose,
characteristics of the sample, methods, level of evidence, study limitations, and application of
evidence.
Reporting Guidelines
The current lack of a standard for IR reporting does not negate the importance of
following an established guideline when reporting the findings of an IR. A few guidelines are
available including the PRISMA mode, and the one followed in this IR, as outlined by
Whittenmore and Knafl (2005). The methodology allows for the inclusion of experimental and
non-experimental research; this review is based on experimental research. The initial stage of
any review is problem identification. This review addresses the safe incorporation of biosimilars
into oncology practice. Problem identification is followed by a literature search, data synthesis,
and data presentation. This review follows these steps in accordance with the proposed
methodology.
DATA ANALYSIS AND SYNTHESIS
Data Analysis Method
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The data analysis method for this IR followed the recommendations of Whittenmore and
Knafl (2005). A constant comparison methodology was used. Initially, all data were
compared item by item. Similar data were grouped together for further comparison. Categories
were coded to allow for further synthesis and analysis. Categories were subdivided into
supportive biosimilars and therapeutic biosimilars. Additional subclassifications included
analytical determination, clinical comparative determination, and switch determination.
Once grouped, the data was analyzed for patterns, themes, and relationships. The data
was assessed for conflicting evidence. Studies were grouped according to commonalities
and generalizations of each group formulated. Formulations were compared and conclusions
developed based on the literature.
Descriptive Results
Review studies comprised five systematic reviews, two meta-analyses, and eight RCTs.
Two of the systematic reviews were concerned with switching from reference biologics to
biosimilars. The remaining reviews focused on the overall safety and efficacy of biosimilars.
The two meta-analyses examined evidence for the incorporation of trastuzumab biosimilars and
growth-factor biosimilars into clinical practice. Seven of the RCTs were double-blind studies
with one single-blind, single-dose evaluation study. Four of the trials were conducted in breast
cancer patients, two in patients with lymphoma, and one trial in healthy male subjects. Oncology
biosimilar drugs reviewed in the studies included those as comparable to reference products for
bevacizumab, pegfilgrastim, rituximab, and trastuzumab.
The systematic review by Barbier et al. (2020) synthesized the available data on
switching between reference biologics and biosimilars. Studies included 21,000 patients and
were composed of RCTs and real-world evidence. Both single and multiple switch studies were
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examined and included filgrastim, rituximab, and trastuzumab. Limitations of the review
included a lack of robust design for most evaluated studies and that the short-term follow-up for
most studies limits the detection of delayed adverse events. The main strength of the study was
the coverage of multiple molecules across a variety of settings. Overall, the data provided no
indication that switching from a refence biologic to a biosimilar was related to any compromise
in safety, efficacy, or immunogenicity.
Cohen et al. (2018) reviewed 90 switching studies (14,224 individuals) to determine if
switching from a reference biologic to a biosimilar would result in altered clinical outcomes,
enhanced immunogenicity, or a compromise in safety or efficacy. The review was limited by
inclusion of only one oncology supportive care biologic, filgrastim. Additionally, most studies
were descriptive and not powered to detect switch-related differences. Across studies, no new
safety signals were reported and no compromise in safety or efficacy was observed.
Coory and Thornton (2019) performed a systematic review of eight publications for
seven randomized endpoints and five trastuzumab biosimilars to assess the evidential role of
randomized clinical endpoint studies in the approval of trastuzumab biosimilars. Although
variability in methods used by individual studies was a weakness, the authors concluded,
according to GRADE, that the totality-of-evidence for trastuzumab biosimilar approvals was less
dependent on end points and more dependent on in vitro analytic characterization of the
biosimilar. Furthermore, this characterization was sensitive enough to detect any clinically
meaningful differences in reference biologics and the corresponding biosimilar.
Yang and colleagues (2019) synthesized current evidence on the efficacy and safety of
monoclonal antibodies relative to their refence biologics among cancer patients. Twenty-three
RCTs were evaluated, eight with biosimilar rituximab, six with biosimilar bevacizumab, and
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nine with biosimilar trastuzumab. Based on the pooled binary outcomes using risk ratio with
95% confidence intervals (CIs), continuous outcomes using weighted mean difference with 95%
CIs, and time-to-event outcomes using hazard ratios (HRs), the existing evidence suggested a
high degree of comparable efficacy and safety between reference monoclonal antibodies and
biosimilar monoclonal antibodies. The strength of the study is that it was the first to
comprehensively evaluate all types of monoclonal antibody biosimilars to reference biologics.
The review was limited by the lack of data for outcomes such as overall survival (OS) and
progression-free survival (PFS). It should be noted that these outcomes are not required for a
demonstration of biosimilarity. Further observational studies incorporating these outcomes will
help to confirm the safety of biosimilars.
In a meta-analysis of randomized clinical trials in breast cancer patients, Botteri et al.
(2018) compared the clinical efficacy and safety of approved or proposed supportive care
biosimilar filgrastim or pegfilgrastim with the reference products. Eight RCTs with a total of
1,843 breast cancer patients were included in the review. Three studies were from Germany, two
from the US, two from Brazil, and one from South Korea. Filgrastim was the reference product
in five studies and pegfilgrastim in three studies. Based on an evaluation of the mean difference
in duration of severe neutropenia, differences in depth of absolute neutrophil count nadir, time to
neutrophil recovery, and incidence of febrile neutropenia, no significant differences were seen in
clinical efficacy or safety between biosimilar and reference filgrastim and pegfilgrastim. The
review was limited by the small number of studies included. The review was the first metaanalysis of supportive care biosimilar medicines.
Using a network meta-analysis, Mengato et al. (2019) compared the HR value of PFS for
patients treated with reference trastuzumab to approved biosimilar trastuzumab MYL-14010.
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Despite the limitation of the review of a specific trastuzumab biosimilar, MYL-14010 was found
to be as effective as its original reference product based on an analysis of the HR values for
biosimilar products, the reference product, and the standard of care.
In a comparison of proposed biosimilar LA-EP2006 with reference pegfilgrastim,
Blackwell et al. (2016) randomized 308 patients with early-stage breast cancer to LA-EP2006 or
reference pegfilgrastim following chemotherapy. The primary endpoint of the study was the
duration of severe neutropenia during cycle 1 with equivalence confirmed if 90% and 95%
confidence intervals were within a 1-day margin. The duration of severe neutropenia was
equivalent between groups, and no differences were seen in terms of safety and efficacy. No
treatment-related binding or neutralizing antibodies against either product were detected during
the study. This provided strength for generalizing the findings to patients receiving
chemotherapy regardless of cancer type.
A single-blind, single-dose study by Hanes et al. (2017) examined the PK equivalence of
proposed biosimilar ABP980 and trastuzumab in 157 healthy male subjects. Following a single
dose of 6 mg/kg of intravenous ABP980 or FDA-licensed trastuzumab, area under the serum
concentration-time curve from time 0 to infinity and maximum observed serum concentration
were measured as a means of establishing equivalence of the products. Using a geometric mean
ratio and 90% CI, the study demonstrated the PK similarity of ABP980 to reference trastuzumab.
No subjects developed binding or neutralizing anti-drug antibodies by the end of the study.
The LILAC study addressed the safety and efficacy of ABP980 compared with reference
trastuzumab in women with human epidermal growth factor-positive (HER2+) early breast
cancer. Seven hundred twenty-five women aged 18 years or older and eligible to receive
chemotherapy were randomized to ABP980 or reference trastuzumab. Co-primary endpoints
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were risk difference (RD) and risk ratio (RR) of pathological complete response in breast tissue
and axillary lymph nodes. Based on local laboratory review of tumor samples, the lower bounds
of the 90% CIs showed non-inferiority. A central lab analysis indicated similar efficacy and
safety for ABP980 and reference trastuzumab. The study may be limited by the fact that clinical
tumor response can vary, and there was no validated standard to differentiate between two
similar products (Minckwitz et al., 2018). The central lab confirmation was a study strength.
The trastuzumab biosimilar PF-05280014 plus paclitaxel was compared to reference
trastuzumab plus paclitaxel for HER2+ metastatic breast cancer by Pegram et al. (2018) in a
randomized, double-blind study of 707 participants with at least one measurable confirmed
metastatic lesion. Participants received standard dose therapy. The primary endpoint was
objective response rate (ORR) by week 25 based on blinded central radiology review. The ORR
was 0.940, and the 95% CI fell within the pre-specified equivalence margin of 0.80-1.25. The
study concluded that when given as a first-line treatment for HER2+ metastatic breast cancer,
PF-05280014 plus paclitaxel demonstrated equivalence to reference trastuzumab plus paclitaxel
in terms of ORR. A strength of the study was that ORR is one of the FDA accepted end points
for demonstrating biosimilarity. The randomized double-blind design and blinded independent
radiograph review were also strengths. A limitation of the study was that it did not evaluate the
current standard of care in the metastatic setting which is dual HER2 blockade with trastuzumab
and pertuzumab.
In a randomized, double-blind, parallel-group study, PF-06439535 (a bevacizumab
biosimilar) was compared with reference bevacizumab, both in combination with paclitaxel and
carboplatin, as first-line treatment for 719 patients with advanced non-squamous, non-small-cell
lung cancer. The primary endpoint was ORR in accordance with RECIST criteria confirmed by
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week 25. Patients treated with the biosimilar achieved an ORR of 44.6% as compared to patients
treated with reference bevacizumab that achieved a 45.3% ORR. The final data after study
completion noted no difference in terms of the safety and efficacy of the two products. There
were no notable differences in PFS or OS. The strength of the study was its design, including the
accepted endpoint for demonstrating biosimilarity. The study was limited by the fact that 85.4%
of enrolling countries are outside the US where chemotherapy availability can vary (Reinmuth et
al., 2019).
A randomized, double-blind, efficacy and safety study of PF-05280586 (biosimilar
rituximab) compared with reference rituximab was conducted in 394 patients with previously
untreated CD20-positive, low-tumor-burden follicular lymphoma. Patients were randomized to
receive 375 mg/m2 of either product on days 1, 5, 8, and 22. The primary endpoint was ORR
assessed at week 26. To establish equivalence, the two-sided 95% CI for the difference in ORR
between the groups had to fall within the prespecified margin of  16%. The secondary
endpoints of PFS, CR, safety, immunogenicity, PKs and PDs were included. The study
demonstrated therapeutic equivalence between the two products across endpoints. A potential
limitation of the study, although not required by the FDA, was that it failed to show equivalence
in every indication for which rituximab is approved. Additionally, subjects received only four
doses of therapy as opposed to the standard eight doses (Sharman et al., 2020).
Viswabandya et al. (2019) conducted a randomized, double-blind, PK equivalence trial
comparing the biosimilar rituximab (DRL-rituximab) with reference rituximab (MabThera) in
patients with diffuse large b-cell lymphoma. A total of 151 untreated patients eligible to receive
CHOP chemotherapy were randomized to CHOP with the biosimilar or CHOP with the reference
product. Equivalence was based on the primary endpoint of PKs following cycle one. Secondary
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endpoints were ORR at cycle six and event-free survival and OS at week 87. Rates of b-cell
depletion were measured. Investigators found no difference between the compounds in terms of
PKs, PDs, safety, and immunogenicity. The study was conducted in a single country. The design
provided strength. The sample size may have limited statistical power.
Xavier et al. (2018) conducted a phase III, randomized, double-blind study comparing the
efficacy, safety, and immunogenicity of SB3 (trastuzumab biosimilar) and reference trastuzumab
for 800 patients treated with neoadjuvant therapy with HER2+ early breast cancer receiving
adjuvant chemotherapy. The primary endpoint was breast pathological complete response rate
(pCR). Equivalence was set if the 95% CI ratio was within the predefined margin of 0.785 to
1.546 or the CI was declared within  13%. Secondary endpoints included complete response
rate (CR), ORR, event-free survival, OS, PKs, and immunogenicity. Equivalence for efficacy
was demonstrated based on the primary endpoint between both products. Antibody development
was not observed. Strengths for the study included the study design and inclusion of OS as a
secondary endpoint.
Synthesis
The types of biosimilars addressed for use in oncology include bevacizumab,
pegfilgrastim, rituximab, and trastuzumab. Eight RCTs comparing the use of one of the above
biosimilars to a reference product found no difference in the efficacy, safety, and
immunogenicity of the products based on the varying clinical endpoints of ORR, pCR, PKs, RD
or RR (Blackwell et al., 2016; Hanes et al., 2016; Minckwitz et al., 2018; Pegram et al., 2018;
Pivot et al., 2018; Reinmuth et al., 2019; Sharman et al., 2020; Viswabandya et al., 2019). The
meta-analysis by Yang et al. (2019) also determined no difference in the efficacy, safety, and
immunogenicity among eight biosimilar and reference monoclonal antibodies. Although not
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required to demonstrate biosimilarity, five studies compared survival either by measuring PFS or
OS and determined no differences in the two among patients treated with a biosimilar versus a
reference product (Mengato et al., 2019; Pivot et al., 2018; Reinmuth et al., 2019; Sharman et al.,
2020; Viswabandya et al., 2019).
Two meta-analyses examined the concept of switching from a reference biologic to a
biosimilar for filgrastim, rituximab, and trastuzumab. Switching products was not associated
with a compromise in outcomes, efficacy, safety, or immunogenicity (Cohen et al., 2018; Coory
& Thornton, 2019). The meta-analysis by Botteri et al. (2018) and the clinical comparative study
by Blackwell et al. (2016) found no differences in the duration of severe neutropenia, safety, or
immunogenicity among supportive care biosimilars (filgrastim; pegfilgrastim) versus the
reference products.
Ethical Considerations
This project was submitted to the Liberty University Institutional Review Board (IRB).
The review board granted an exempt, no human subject research status on May 27, 2021. A copy
of the IRB decision can be found in Appendix B. Biomedical research training has been
completed through the Collaborative Institutional Training Initiative (see Appendix C).
Timeline
The timeline for this project includes the following phases: pre-proposal, project proposal
submission, and final project submission. Final project defense took place on July 22, 2021.
DISCUSSION
Prior to routinely introducing biosimilars into oncology clinic practice, it is necessary to
establish that adult patients diagnosed with cancer can be treated with biosimilars as compared to
reference biologics without a compromise in safety and efficacy over the course of therapy.
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Demonstrating the safety and efficacy of biosimilars requires that the biosimilar product be
highly similar to its reference product. The evidence supporting similarity is predicated on robust
data from analytical, PK/PD, nonclinical, and clinical studies as outlined in the abbreviated
approval process for biosimilars (Mengato et al., 2019). Clinical studies are important for
revealing any clinically meaningful differences between the biosimilar and the reference biologic
in terms of safety, efficacy, and immunogenicity.
High-quality evidence from four systematic reviews/meta-analyses suggests that
biosimilar trastuzumab used as treatment for breast cancer (metastatic, neoadjuvant, adjuvant) is
equivalent to reference trastuzumab in terms of overall response rate (ORR), hazard ratio (HR),
progression free survival (PFS), and safety. Four RCTs comparing biosimilar trastuzumab to the
reference product show similar PK profiles (healthy males) as well as similar safety and efficacy
in terms of ORR, PFS, overall survival (OS), duration of response (DOR), and pathologic
complete response rate (pCR) in women with breast cancer. Two of the RCTs focus on
biosimilar ABP980 which is now approved in the US. ABP980 demonstrated PK equivalency
and similar efficacy as compared to the reference product. In studies evaluating ABP980, antidrug antibodies (ADAs) were not found.
High-grade evidence from two systematic reviews indicates that biosimilar bevacizumab
is highly similar in terms of safety and efficacy as compared to the reference product when used
in combination with chemotherapy in patients with lung and colon cancer. PK values are
equivalent between the two products. No new safety signals or immunogenicity concerns are
identified in comparing products. A RCT comparing biosimilar and refence bevacizumab in
combination with chemotherapy in lung cancer patients documents similarity of the products in
terms of ORR and PFS among group participants.
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High-grade evidence from two systematic reviews establishes a high degree of similarity
between reference rituximab and biosimilar rituximab in terms of PK/PD profiles, efficacy,
safety, and immunogenicity using ORR as the clinical endpoint. Testing was conducted in
populations with b-cell disorders such as lymphoma and chronic lymphocytic leukemia. Two
RCTs confirm similar safety and efficacy of biosimilar rituximab as compared to reference
rituximab in terms of ORR, PFS, OS, and DOR. Biosimilar and reference rituximab have similar
rates of b-cell depletion.
Granulocyte colony-stimulating factors (pegfilgrastim and filgrastim) are routinely used
to prevent neutropenia and support cancer patients undergoing myelosuppressive chemotherapy
(Botteri et al., 2018). Biosimilar versions of these support factors are available in the US.
Adoption of supportive care medicines continues to lag due to clinician concerns and lack of
safety awareness. High-grade evidence from a systematic review and a meta-analysis of
supportive care biosimilars among different populations demonstrates highly similar efficacy and
safety outcomes for supportive care biosimilars as compared to reference products.
Switching patients from a reference product to a biosimilar has created concern among
clinicians regarding the potential for immunogenicity and the development of ADAs or
neutralizing drug antibodies (NDAs) secondary to the switching process. Analysis of data from
this IR involving systematic reviews evaluating switch studies in over 21,000 patients
determined that switching from a reference product to a biosimilar product is not associated with
a compromise in drug safety or efficacy. The development of ADAs or ANAs is not an issue
when switching from a reference product to a biosimilar and vice versa.
Based on an analysis of the data at hand, the abbreviated pathway for biosimilar approval
is scientifically sound. The approval process allows for the establishment of biosimilarity and a

BIOSIMILAR INTEGRATION

30

determination that biosimilars are as safe and efficacious as reference biologics. The pooled
analysis suggests that incorporating biosimilars into oncology clinical practice can be done safely
without concerns for compromised efficacy. Using a biosimilar or switching to a biosimilar is
not associated with immunogenicity issues. Although biosimilarity is established early in the
approval pathway by analytical studies, data from the phase III clinical comparative study is
essential to examine when making a choice to incorporate biosimilars into oncology clinical
practice.
Limitations
This IR has several limitations. The simplicity of the search terms “biosimilars” and
“oncology” may have led to missing data. A methodological limitation may exist in that only
high-quality evidence is presented. Data analysis does not include all US approved biosimilars.
Outcomes varied across studies. Biosimilarity is evaluated in mainly breast, lung, and lymphoma
populations, which make the findings in this IR not generalizable to other populations.
Implications for Practice/Future Work
The incorporation of biosimilars into oncology clinical practice can be safely adopted
with the bonus of cost savings across the healthcare sector. Much of the adoption may be
influenced by institutional formularies and third-party payer requirements. Advance practice
providers (APPs) must seek opportunities to participate in formulary selection and can serve as
sources for reviewing evidence that supports biosimilar adoption. APPs can provide education
for key stakeholders and patients. APPs can serve at the local, state, or federal levels to provide
guidance regarding policies that regulate biosimilarity and interchangeability. APPs must
understand the value and interpretation of clinical comparative studies and participate as
investigators in the biosimilar clinical trial process.
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Dissemination
The findings of this IR will be submitted to a peer-reviewed journal, the target journal is
The Journal of the Advanced Practitioner in Oncology. Submissions are required in APA format.
The journal is available online and targets all advanced practice providers, including
pharmacists. An abstract will be submitted to JADPROLive 2021 ahead of an anticipated poster
presentation.
CONCLUSION
As the US population ages and an increasing number of patients are diagnosed with
cancer, the demand for therapeutic biologics is expected to increase. The escalating costs of
biologics may hinder patient access to them, thereby negatively impacting patient outcomes. The
BPCI Act provides a sound regulatory approval process for highly similar biologics (biosimilars)
that can be introduced at a lower cost, thereby increasing patient access to needed biologics.
Systematic reviews, meta-analyses, and RCTs evaluated in this review find no differences in
terms of safety, efficacy, and immunogenicity of biosimilars as compared to reference supportive
care and therapeutic biologics. These findings support that biosimilars can be safely adopted into
oncology clinical practice. Ongoing studies and new biosimilar approval studies must continue to
confirm this conclusion.
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Table 1
Biosimilar and Generic Drug Comparison
Biologic

Generic

Type
Protein-based
Chemically based
Production
Living cell lines
Chemical synthesis
Size
Large (1000 x)
Small
Molecular Weight
High
Low
Structure
Complex/heterogeneous
Simple/defined
Characterization
Full characterization not possible
Complete
Immunogenicity
Immunogenic
Low potential
Note: Adapted from “Biologics and biosimilars: Role in modern pharmacotherapy and
importance of pharmacovigilance,” by R. R. Alachandani, B. M. Sattigeri, and P. S.
Karelia. International Journal of Research in Medical Sciences, 2(2), 382-386. Copyright
2014 Alamchandani RR et al.
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Table 2
List of Currently Approved Biosimilars
Biosimilar

Approval Date

Abrilada (adalimumab-afzb)
November 2019
Amjevita (adalimumab-atto)
September 2016
Avsola (infliximab-axxq)
December 2019
Cyltezo (adalimumab-adbm)
August 2017
Erelzi (etanercept-szzs)
August 2016
Eticovo (etanercept-ykro)
April 2019
Fulphila (pegfilgrastim-jmdb)
June 2018
Hadlima (adalimumab-bwwd)
July 2019
Herzuma (trastuzumab-pkrb)
December 2018
Hulio (adalimumab-fkjp)
July 2020
Hyrimoz (adalimumab-adaz)
October 2018
Inflectra (infliximab-dyyb)
April 2016
Ixifi (infliximab-qbtx)
December 2017
Kanjinti (trastuzumab-anns)
June 2019
Mvasi (bevacizumab-awwb)
September 2017
Nivestym (filgrastim-aafi)
July 2018
Nyvepria (pegfilgrastim-apgf)
June 2020
Ogivri (trastuzumab-dkst)
December 2017
Ontruzant (trastuzumab-qyyp)
January 2019
Renflexis (infliximab-abda)
May 2017
Retacrit (epoetin alfa-epbx)
May 2018
Riabni (rituximab-arrx)
December 2020
Ruxience (rituximab-pvvr)
July 2019
Trazimera (trastuzumab-qyyp)
March 2019
Truxima (rituximab-abbs)
November 2018
Udenyca (pegfilgrastim-cbqv)
November 2018
Zarxio (filgrastim-sndz)
March 2015
Ziextenzo (pegfilgrastim-bmez)
November 2019
Zirabev (bevacizumab-bvzr)
June 2019
Note: Adapted from “Biosimilars,” Food and Drug Administration, https://www.fda.gov/drugs/
biosimilars/biosimilar-product-information. Copyright 2021 by the Food and Drug
Administration.
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Appendix A
Levels of Evidence

Article Title, Author, etc.
(Current APA Format)

Study
Purpose

Barbier et al. (2020). The
efficacy, safety, and
immunogenicity of switching
between reference
biopharmaceuticals and
biosimilars: A systematic
review. Clinical Pharmacology
& Therapeutics, 108(4), 734755.
https://dx.doi.org/10.1002/cpt.1
836

To
synthesize
the
available
data on
switching
from a
reference
product to
a
biosimilar
and assess
if
switching
affects
efficacy,

Sample
(Character
istics of the
Sample:
Demograp
hics, etc.)

178 studies
comprised
of RCTs
and real
world
evidence.
Studies
included
21,000
switched
patients.

Methods

A systematic
literature review
was carried out
up to the 19th of
June 2018 in the
biomedical
databases
Embase,
Medline,
Cochrane and
Web of Science.
Search results
were manually
screened based
on predefined
inclusion and

Study
Results

Switching
from a
reference
biologic to
a biosimilar
does not
result in
any major
efficacy,
safety, or
immunogen
icity issues.

Would
Use as
Level of
Evidence
Evidenc
to
Study
e (Use
Support a
Limitation
Melnyk
Change?
s
Framew
(Yes or
ork)
No)
Provide
Rationale.
Level 1:
Systemat
ic
review
of RCTs
and realworld
evidence

Short-term
follow-up
of studies
does not
provide
sensitivity
to detect
rare AEs.

Yes.
Would
only use it
to support
a change
in the
biosimilar
s studies
in the
review.
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Study
Purpose

Sample
(Character
istics of the
Sample:
Demograp
hics, etc.)

safety, or
immunoge
nicity
outcomes.
Blackwell et al. (2016). A
comparison of proposed
biosimilar LA-EP2006 and
reference pegfilgrastim for the
prevention of neutropenia in
patients with early-stage breast
cancer receiving
myelosuppressive adjuvant or
neoadjuvant chemotherapy:
Pegfilgrastim randomized
oncology (supportive care) trial
to evaluate comparative
treatment (PROTECT-2), a
phase III, randomized, doubleblind trial. The Oncologist, 21,
789-794.

A
confirmato
ry efficacy
and safety
study
designed
to compare
proposed
biosimilar
LAEP2006
with
reference
pegfilgrast
im in
early-stage

Methods

Study
Results

Would
Use as
Level of
Evidence
Evidenc
to
Study
e (Use
Support a
Limitation
Melnyk
Change?
s
Framew
(Yes or
ork)
No)
Provide
Rationale.

exclusion
criteria.

308 women
>/= 18
years of age
with
histological
ly proven
early-stage
breast
cancer
eligible for
neoadjuvant
or adjuvant
treatment
with
docetaxel,
doxorubicin

Patients
randomized 1:1
to LA-EP2006
or reference
pegfilgrastim
(Neulasta) on
day 2 of each
cycle of therapy.

Duration of
severe
neutropenia
was
equivalent
between
groups in
cycle one.

Primary
endpoint:
duration of
severe
neutropenia
during cycle 1
with equivalence

Safety
profiles
were also
similar
between
groups.

Level 2:
RCT

May be
difficult to
compare
patientreported
AEs across
trials due
to
differences
in
recording
AEs in
actual
clinical
settings.

Yes.
Evidence
supports
the use of
the
biosimilar
Neulasta
following
chemother
apy that
results in
high rates
of febrile
neutropeni
a,
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Sample
(Character
istics of the
Sample:
Demograp
hics, etc.)

Article Title, Author, etc.
(Current APA Format)

Study
Purpose

http://dx.doi.org/10.1634/theon
cologist.2016-0011

breast
cancer
patients
receiving
adjuvant or
neoadjuva
nt
myelosupp
ressive
chemother
apy.

,
cyclophosp
hamide
chemothera
py.

To
compare
the clinical
efficacy
and safety
of
approved
or

8 RCT
studies
published
between
2008 and
2016.

Botteri et al. (2018).
Comparing granulocyte colonystimulating factor filgrastim
and pegfilgrastim to its
biosimilar in terms of efficacy
and safety: A meta-analysis of
randomized clinical trials in
breast cancer patients.

Methods

Study
Results

confirmed if
90% and 95%
CIs were within
pre-defined
margins.

No ANAs
were
detected.

Literature search
using
Pubmed/Medline
using serach
strings:
Filgrastim breast
cancer and

No
statistically
significant
difference
in duration
of severe
neutropenia
between

Would
Use as
Level of
Evidence
Evidenc
to
Study
e (Use
Support a
Limitation
Melnyk
Change?
s
Framew
(Yes or
ork)
No)
Provide
Rationale.
independe
nt of
tumor
type.

ECOG PS
0-2.
Disease
stage I-III.

1843
patients

Level 1:
Metaanalysis
of RCTs.

Small
number of
studies
included in
the
analysis.

Yes.
Results
support
the use of
biosimilar
G-CSF for
supportive
care in
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Sample
(Character
istics of the
Sample:
Demograp
hics, etc.)

Article Title, Author, etc.
(Current APA Format)

Study
Purpose

European Journal of Cancer,
89, 49-55.
https://doi.org/10.1016/j.ejca.20
17.10.034

proposed
G-CSF
biosimilars
(filgrastim
or
pegfilgrast
im) with
reference
G-CSF in
breast
cancer
patients.

with breast
cancer
included.

To
determine
if

90
switching
studies

Cohen, et al. (2018). Switching
reference medicines to
biosimilars: A systematic

Methods

Pefgilgrastim
breast cancer.
Primary end
point duration of
severe
neutropenia
during cycle 1.
Secondary end
point safety.
Statistical
analysis per SAS
software version
9.4.

Systematic
search using
Medline and

Study
Results

Would
Use as
Level of
Evidence
Evidenc
to
Study
e (Use
Support a
Limitation
Melnyk
Change?
s
Framew
(Yes or
ork)
No)
Provide
Rationale.

reference
and
biosimilar
G-CSF.

patients
receiving
myelosuppressiv
e therapy.

No safety
differences
between
reference
and
biosimilar
G-CSF

The risk of
immunogen
icity-related

Has
clinical
implicatio
ns for the
choice of
G-CSF to
be used in
clinic and
provides
for cost
savings.
Level 5: Variability
Systemat in methods
ic
used by

Yes.
It would
be
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Article Title, Author, etc.
(Current APA Format)

Study
Purpose

literature review of clinical
outcomes. Drugs, 78, 463-478.
https://doi.org/10.1007/s40265018-0881-y

switching
from a
reference
biologic to
a
biosimilar
leads to
altered
clinical
outcomes,
enhanced
immunoge
nicity,
compromis
ed safety,
or
decreased
efficacy
for
patients.

Sample
(Character
istics of the
Sample:
Demograp
hics, etc.)

evaluating
supportive
care and
therapeutic
agents.
14,225
unique
individuals.
Seven
different
molecular
entities.
14 disease
states.

Methods

Embase
databases up to
June 30, 2017,
using terms
biosimilar
pharmaceuticals
or biologic
factors.
End points
reported in
descriptive
manner.

Study
Results

safety
concerns or
diminished
efficacy is
unchanged
after
switching
from a
reference
biologic to
a biosimilar
medicine.

Would
Use as
Level of
Evidence
Evidenc
to
Study
e (Use
Support a
Limitation
Melnyk
Change?
s
Framew
(Yes or
ork)
No)
Provide
Rationale.
literature
review
of
predomi
nantly
descripti
ve
studies.

individual
studies.

supportive
but not on
its own
Majority of
merit.
studies
descriptive Could be
combined
in nature
and not
with
powered or additional
designed to evidence
detect
to support
switchswitching.
related
differences
.
Not
possible to
pool
studies in a
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Study
Purpose

Sample
(Character
istics of the
Sample:
Demograp
hics, etc.)

Methods

Study
Results

Would
Use as
Level of
Evidence
Evidenc
to
Study
e (Use
Support a
Limitation
Melnyk
Change?
s
Framew
(Yes or
ork)
No)
Provide
Rationale.
metaanalysis.

Coory, M., & Thornton, K.
(2019). Randomized clinical
endpoint studies for
trastuzumab biosimilars: A
systematic review. Breast
Cancer Research and
Treatment, 176, 17-25.
https://doi.org/10.1007/s10549019-05227-7

To assess
the
evidential
role of
randomize
d clinical
endpoint
studies in
the
marketing
approval
of
trastuzuma
b
biosimilars
.

Seven
randomized
clinical
endpoint
studies for
five
trastuzumab
biosimilars

PubMed and
ClinicalTrials.go
vsearch of
randomized
studies up to
January 31, 2019
using the term
trastuzumab
biosimilar.

Using
surrogate
endpoints,
each
biosimilar
was not
different
from
Herceptin
in any
clinically
important
way.

Level 1:
Systemat
ic
review
of RCTs.

Studies not
powered
for safety
endpoints.
Small
sample
size (100
to 500 in
each arm).

Yes. Best
use of this
review
would be
to adopt
biosimilar
s into
practice
by
assessing
in vitro
data as
opposed to
long-term
clinical
outcomes
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Study
Purpose

Sample
(Character
istics of the
Sample:
Demograp
hics, etc.)

Methods

Study
Results

Would
Use as
Level of
Evidence
Evidenc
to
Study
e (Use
Support a
Limitation
Melnyk
Change?
s
Framew
(Yes or
ork)
No)
Provide
Rationale.
such as
progressio
n free
survival or
overall
survival.

Hanes et al. (2017). A
randomized, single-blind,
single-dose study evaluating
the pharmacokinetic
equivalence of proposed
biosimilar ABP 980 and
trastuzumab in healthy male
subjects. Cancer
Chemotherapy and
Pharmacology, 79, 881-888.
https://doi.org/10.1007/s00280017-3286-9

Compare
the
pharmacok
inetic (PK)
profiles of
biosimilar
ABP 980
and
reference
trastuzuma
b.

157 healthy
males ≥ 18
years of age
but ≤ 45
years of
age.

Conducted in
accordance with
the Declaration
of Helsinki and
the ICH E6
Guidelines on
Good Clinical
Practice.

The study
Level 2:
demonstrate RCT.
d similarity
of ABP 980
to both EU
and US
trastuzumab
.

Randomized,
single-blind,
single-dose,
three-arm,

No
differences
in safety
and
tolerability

ANAs not
centrally
confirmed.

Yes.
Establishe
s the
biosimilari
ty of
trastuzuma
b-anns.
Supports
use of the
biosimilar
in place of
the
reference
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Study
Purpose

Sample
(Character
istics of the
Sample:
Demograp
hics, etc.)

Methods

parallel-group
study.
Subjects
randomized
1:1:1 to single
infusion ABP90,
trastuzumab
(US) or
trastuzumab
(EU)
PK parameters
calculated using
noncompartmental
techniques
(WinNonlin
Professional
Network

Study
Results

noted
among
treatments.

Would
Use as
Level of
Evidence
Evidenc
to
Study
e (Use
Support a
Limitation
Melnyk
Change?
s
Framew
(Yes or
ork)
No)
Provide
Rationale.
product in
approved
indications
.
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Study
Purpose

Sample
(Character
istics of the
Sample:
Demograp
hics, etc.)

Methods

Study
Results

Would
Use as
Level of
Evidence
Evidenc
to
Study
e (Use
Support a
Limitation
Melnyk
Change?
s
Framew
(Yes or
ork)
No)
Provide
Rationale.

Edition, Version
6.3).
Safety analysis
included
descriptive
summaries of
AEs and
incidence of
ADAs.
Jacobs et al. (2017).
Biosimilars for the treatment of
cancer: A systematic review of
published evidence. BioDrugs,
31, 1-36.
http://doi.org/10.1007/s40259016-0207-0

To collate
all
published
data to
assess the
weight of
available
evidence
for
proposed

36
publications
involving
23 studies
in oncology
and chronic
inflammato
ry diseases
for
bevacizuma

Search of
Medline,
Embase,
ClinicalTrials.go
v,National
Library of
Science and ISI
Web of Science
databases up to
September 2015.

The
proposed
biosimilars
exhibit
close
similarity to
their
originators.

Level 1:
Systemat
ic
review
of
controlle
d
studies.

At the time
of analysis,
limited
outcomes
data were
available
from
published
conference

Yes.
Determini
ng
biosimilari
ty is not
dependent
on
outcomes
data but
rather on

BIOSIMILAR INTEGRATION

Article Title, Author, etc.
(Current APA Format)

Mengato et al. (2019).
Trastuzumab biosimilar in
metastatic breast cancer:
Evaluating equivalence with
originator using network metaanalysis. International Journal
of Clinical Pharmacology and
Therapeutics, 57(3), 160-162.
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Sample
(Character
istics of the
Sample:
Demograp
hics, etc.)

Methods

monoclona
l antibody
biosimilars
and
intended
copies for
the
treatment
of cancer.

b,
rituximab,
and
trastuzumab
originators.

Search of
conference
proceedings
from 2012 to
July 2015.

To
demonstrat
e that
MYL14010
biosimilar
trastuzuma
b is as
effective

8 RCT
involving
the use of
trastuzumab
MYL14010
and
originator
trastuzumab
.

Medline and
Pubmed search
using words
trastuzumab,
Herceptin, and
metastatic breast
cancer.

Study
Purpose

Study
Results

Would
Use as
Level of
Evidence
Evidenc
to
Study
e (Use
Support a
Limitation
Melnyk
Change?
s
Framew
(Yes or
ork)
No)
Provide
Rationale.
s abstracts
only.
Molecules
unable to
be
compared
like for
like.

MYL14010
biosimilar
is as
effective as
its
originator
in terms of
HR and
PFS.

Level 1:
Metaanalysis
of RCTs.

Clinical
trial
informatio
n extracted
only from
ClinicalTri
als.gov so
some
studies

proving
degree of
similarity.
This
review
supports
the use of
the
biosimilar
s studied.
Yes.
Analysis
supports
the use of
Mylan’s
biosimilar
trastuzuma
b-dkst for
any

BIOSIMILAR INTEGRATION

50

Sample
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istics of the
Sample:
Demograp
hics, etc.)

Article Title, Author, etc.
(Current APA Format)

Study
Purpose

https://doi.org/10.5414/CP2033
51

as its
originators
in terms of
hazard
ratio of
PFS.

Pooled
analysis
with 1,955
patients.

Results filtered
by article type
(meta-analysis).

could have
been
missed.

Comparison of
hazard ratio
values for
biosimilar and
originator
trastuzumab. CI
95%.

Only 17
conference
s were
searched
and some
proceeding
could have
been
missed.

To
compare
the clinical
safety and
efficacy of
ABP 980

725 women
aged 18
years or
older, had
histological
ly

RCT,
multicenter,
double-blind,
active-controlled
equivalence trial.

Minckwitz et al. (2018).
Efficacy and safety of ABP980
compared with reference
trastuzumab in women with
HER2-positive early breast
cancer (LILAC study): A

Methods

Study
Results

Would
Use as
Level of
Evidence
Evidenc
to
Study
e (Use
Support a
Limitation
Melnyk
Change?
s
Framew
(Yes or
ork)
No)
Provide
Rationale.

ABP 980
Level 2:
and
RCT.
trastuzumab
had similar
safety
outcomes in

Local and
central labs
did not
agree on
predefined

indication
in which
the
reference
product is
indicated.

Yes.
LILAC
study
supports
use of
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Article Title, Author, etc.
(Current APA Format)

Study
Purpose

randomized, double-blind,
phase 3 trial. Lancet Oncology,
19, 987-998.
http://dx.doi.org/10.1016/s1470
-2045(18)30241-9

with that
of
trastuzuma
b in
women
with
HER2positive
early
breast
cancer.

Sample
(Character
istics of the
Sample:
Demograp
hics, etc.)

confirmed
HER2positive
invasive
early breast
cancer, an
Eastern
Cooperative
Oncology
Group
performanc
e status
score of 0
or 1, and
were
planning to
have
surgical
resection of
the breast
tumor with
sentinel or

Methods

Patients assigned
1:1 to receive
ABP 980 or
trastuzumab with
a permuted
block design
computergenerated
randomization
schedule.
Co-primary
efficacy
endpoints risk
difference and
risk ratio of
pathological
complete
response in
breath tissue and

Study
Results

both the
neoadjuvant
and
adjuvant
phases of
the study.

Would
Use as
Level of
Evidence
Evidenc
to
Study
e (Use
Support a
Limitation
Melnyk
Change?
s
Framew
(Yes or
ork)
No)
Provide
Rationale.
equivalenc
e margins.

biosimilar
trastuzuma
b-anns
Clinical
where
response of
reference
breast
trastuzuma
cancer to
b is
neoadjuva
indicated
nt therapy
based on
not
central
assessed.
confirmati
on of
equivalenc
e.
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Study
Purpose

Sample
(Character
istics of the
Sample:
Demograp
hics, etc.)

Methods

Study
Results

Would
Use as
Level of
Evidence
Evidenc
to
Study
e (Use
Support a
Limitation
Melnyk
Change?
s
Framew
(Yes or
ork)
No)
Provide
Rationale.

axillary
axillary lymph
lymph node nodes.
dissection
and
neoadjuvant
chemothera
py.
Pegram et al. (2018). PF05280014 (a trastuzumab
biosimilar) plus paclitaxel
compared with reference
trastuzumab plus paclitaxel for
HER2-positive metastatic
breast cancer: A randomized
double-blind study. British
Journal of Cancer, 120, 172182.
https://doi.org/10.1038/s41416018-0340-2

To
compare
PF05280014
(biosimilar
) with
reference
trastuzuma
b.
Primary
end point

707 females
ages ≥ 18
years with
HER2+
metastatic
breast
cancer with
at least one
measurable
lesion by
RECIST
criteria.

1:1
randomization
from 4/4/14 to
1/22/16 to IV
PF-05280014 or
trastuzumab-EU
in standard dose.
Randomization
via automated
interactive webbased response
system.

When given Level 2:
as first-line RCT
therapy for
HER2+
metastatic
breast
cancer, PF05280014
demonstrate
d
equivalence
to reference

Study did
not assess
current
standard
first-line
treatment
with dual
HER2
blockade.

Yes.
Evidence
supports
no
clinically
meaningfu
l
difference
in PF05280014
with
paclitaxel
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Study
Purpose

RR for
ORR.

Sample
(Character
istics of the
Sample:
Demograp
hics, etc.)

Methods

Investigators
blinded to
treatment arms.
Primary end
point: ORR.

Study
Results

Would
Use as
Level of
Evidence
Evidenc
to
Study
e (Use
Support a
Limitation
Melnyk
Change?
s
Framew
(Yes or
ork)
No)
Provide
Rationale.

trastuzumab
-EU in
terms of
ORR.

verses
reference
trastuzuma
b.

No
statistically
significant
differences
in PFS, OS,
or DOR
were
observed.

Outcomes
were equal
among
both
groups.
Study also
supports
confirmato
ry trials
with dual
blockade
therapy.
Biosimilar
now
approved
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Study
Purpose

Sample
(Character
istics of the
Sample:
Demograp
hics, etc.)

Methods

Study
Results

Would
Use as
Level of
Evidence
Evidenc
to
Study
e (Use
Support a
Limitation
Melnyk
Change?
s
Framew
(Yes or
ork)
No)
Provide
Rationale.
in the US
under the
brand
name
Trazimera.

Reinmuth et al. (2019). PF06439535 (a bevacizumab
biosimilar) compared with
reference bevacizumab
(Avastin), both plus paclitaxel
and carboplatin, as first-line
treatment for advanced nonsquamous non-small-cell lung
cancer: A randomized, doubleblind study. BioDrugs, 33, 555570.
https://doi.org/10.1007/s40259019-00363-4

To
compare
PF06439535
(biosimilar
) with
reference
bevacizum
ab, both
with
caboplatin
and
paclitaxel
as first-line
therapy for

719 adult
patients
ages ≥ 18
years with
nonsquamous,
newly
diagnosed
stage IIIB
or IV
NSCLC or
recurrent
NSCLC.
Patients
required to

1:1
randomization to
PF-06439535
plus paclitaxel
and carboplatin
or reference
bevacizumabEU plus
paclitaxel and
carboplatin.

Among
Level 2:
patients
RCT
with
advanced
nonsquamous,
NSCLC,
PF06439535
demonstrate
d similarity
Randomized was
to reference
computerbevacizuma
generated.
b-EU in

Majority of
recruitmen
t was from
10
countries
outside the
US.

Yes.
Study
does
support
the
validity of
biosimilari
ty but was
conducted
using EUbased
products.
Adds to
the body
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Purpose

advanced
nonsquamous
NSCLC.
Primary
end point
ORR.

Sample
(Character
istics of the
Sample:
Demograp
hics, etc.)

have one
measurable
lesion by
RECIST
criteria.

Methods

Study
Results

Investigators
blinded to arms.

terms of
efficacy.

Randomized
5/21/15 to
11/14/16.

Safety
profiles of
both
products
were
comparable.

Primary
endpoint: ORR.

Would
Use as
Level of
Evidence
Evidenc
to
Study
e (Use
Support a
Limitation
Melnyk
Change?
s
Framew
(Yes or
ork)
No)
Provide
Rationale.
of safety
data for
biosimilar
s and
supports
the use of
USbiosimilar
Avastin.
PF06439535
is now
approved
in the US
under the
brand
name
Zirabev.
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Study
Purpose

Sharman et al. (2020). A
randomized, double-blind,
efficacy and safety study of PF05280586 (a rituxan biosimilar)
compared with Rituximab
reference product (MabThera)
in subjects with previously
untreated CD20-positive, lowtumor-burden follicular
lymphoma (LTB-FL).
BioDrugs, 34, 171-181.
https://doi.org/10.1007/s40259019-00398-7

Compare
PF05280586
(biosimilar
) with
reference
rituxmab
in subjects
with
previously
untreated
CD20positive,
lowtumorburden
follicular
lymphoma
(LTB-FL).

Sample
(Character
istics of the
Sample:
Demograp
hics, etc.)

394 adults
ages ≥ 18
years with
CD20+
LTB-FL
without
lymphomarelated B
symptoms,
ECOG PS
0-1

Methods

Web-based
automatedresponse system
used for 1:1
randomization to
375 mg/m2 of
PF-05280586 or
rituximab-EU
once weekly for
4 weeks.
Subjects
stratified by
FLIPI2 scores.
Primary
endpoint:
efficacy and
ORR.
Secondary
endpoints: PFS,

Study
Results

The safety,
efficacy,
immunogen
icity, PK
and PD
were
similar
between
both PF05280586
and
rituximabEU up to 52
weeks.
CR rates
were
similar.

Would
Use as
Level of
Evidence
Evidenc
to
Study
e (Use
Support a
Limitation
Melnyk
Change?
s
Framew
(Yes or
ork)
No)
Provide
Rationale.
Level 2:
RCT

Does not
show that
biosimilar
is
equivalent
in every
indication
for which
rituximab
is
approved
(this is not
required by
the FDA).
Subjects
received
four doses
as opposed
to eight
doses, the

Yes.
PF05280058
6 is now
licensed in
the US as
Ruxience.
Evidence
supports
that PF05280586
is
equivalent
to
reference
rituximab
without a
compromi
se in
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Study
Purpose

Sample
(Character
istics of the
Sample:
Demograp
hics, etc.)

Primary
end point
ORR.

Viswabandya et al. (2019).
Randomized, double-blind,
pharmacokinetic equivalence
trial comparing DRL-rituximab
with mabthera in patients with
diffuse large b-cell lymphoma.
Journal of Global Oncology, 5,
1-13.
https://doi.org/10.1200/JGO.19.
00248

To
compare
the
pharmacok
inetics
(PKs) of
DRLrituximab
biosimilar
and
originator

Methods

Study
Results

Would
Use as
Level of
Evidence
Evidenc
to
Study
e (Use
Support a
Limitation
Melnyk
Change?
s
Framew
(Yes or
ork)
No)
Provide
Rationale.

CR at 26 weeks,
TTF, DOR, OS,
safety, and
immune events.

151 patients
with
untreated
DLBCL
who were
eligible to
receive
cyclophosp
hamide,
doxorubicin
,

Patients were
randomly
assigned at a
one-to-one ratio
to receive
DRL_RI or
RMP for six 21day cycles of
rituximab plus
CHOP, with 18
months of
follow-up after

standard of
care.
Interpretati
on of AE
data may
be limited
by size of
the study.
Rates for B- Level 2:
cell
RCT.
depletion/re
pletion,
immunogen
icity, and
adverse
events were
comparable
in both
groups.

Study
conducted
in single
country.

efficacy or
safety
when used
instead of
brand
name
rituximab.

No.
Study
does
confirm
biosimilari
ty but
approval
of this
product
has not
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Purpose

rituximab
mabthera.

Sample
(Character
istics of the
Sample:
Demograp
hics, etc.)

vincristine,
and
prednisone
(CHOP)
therapy.

Methods

day 1, cycle 6
(C6). Primary
end point was
C1 PKs,
measured as area
under the plasma
concentrationtime curve from
day 0 to 21
(AUC0-21 days)
and maximum
plasma
concentration
(Cmax).
Equivalence was
defined as 90%
CIs for the
DRL_RI/RMP
geometric mean
ratios (GMRs)
within 80% and
125%.

Study
Results

Both the
biosimilar
and
reference
rituximab
have
equivalent
PKs.

Would
Use as
Level of
Evidence
Evidenc
to
Study
e (Use
Support a
Limitation
Melnyk
Change?
s
Framew
(Yes or
ork)
No)
Provide
Rationale.
cleared the
FDA.

BIOSIMILAR INTEGRATION

Article Title, Author, etc.
(Current APA Format)

59

Study
Purpose

Sample
(Character
istics of the
Sample:
Demograp
hics, etc.)

Methods

Secondary end
points included
efficacy
noninferiority
measured by
objective
response rate
(ORR) at C6 and
event-free
survival and
overall survival
at 87 weeks, PK
equivalence at
C6 and PD
equivalence (rate
of B-cell
depletion and
repletion),
safety, and
immunogenicity.

Study
Results

Would
Use as
Level of
Evidence
Evidenc
to
Study
e (Use
Support a
Limitation
Melnyk
Change?
s
Framew
(Yes or
ork)
No)
Provide
Rationale.
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Article Title, Author, etc.
(Current APA Format)

Study
Purpose

Xavier et al. (2018). Phase III,
randomized, double-blind study
comparing the efficacy, safety,
and immunogenicity of SB3
(trastuzumab biosimilar) and
reference trastuzumab in
patients treated with
neoadjuvant therapy for human
epidermal growth factor
receptor 2- positive early breast
cancer. Journal of Clinical
Oncology, 36(10), 968-974.
https://doi.org/10.1200/JCO.20
17.74.0126

To
compare
SB3
(biosimilar
) with
reference
trastuzuma
b in
patients
treated
with
neoadjuva
nt therapy
for human
epidermal
growth
factor
receptor 2positive
early

Sample
(Character
istics of the
Sample:
Demograp
hics, etc.)

Methods

800 females Block stratified
ages 18 to
randomization
65 years.
1:1 to receive
either SB3 or
ECOG PS 0
EU-sourced
to 1.
tratuzumab IV
every 3 weeks in
Patients
the neoadjuvant
with
setting for 8
confirmed
cycles
primary
concurrently
invasive
adenocarcin with standard
dose
oma of the
chemotherapy.
breast,
HER2+.
Primary
endpoints:
efficacy, safety,
PK,
immunogenicity.

Study
Results

Would
Use as
Level of
Evidence
Evidenc
to
Study
e (Use
Support a
Limitation
Melnyk
Change?
s
Framew
(Yes or
ork)
No)
Provide
Rationale.

Equivalenc Level 2:
e for
RCT
efficacy
was
demonstrate
d between
SB3 and
trastuzumab
on the basis
of the ratio
of bpCR
rates.
No
clinically
meaningful
differences
in terms of
safety and
immunogen
icity

Different
product
lots were
used for
the
reference
drug
leaving
room for
drift which
may or
may not
impact
study
results.

Yes.
SB3 is
now
approved
in the US
under the
name
Ontruzant.
This
evidence
supports
the
biosimilari
ty of
Ontruzant
to
reference
brand
trastuzuma
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Study
Purpose

Sample
(Character
istics of the
Sample:
Demograp
hics, etc.)

Methods

breast
cancer.

between the
two
products.

Primary
end point

Yang et al. (2019). Efficacy
and safety of anti-cancer
biosimilars compared to
reference biologics in
oncology: A systematic review
and meta-analysis of
randomized controlled trials.
BioDrugs, 33, 357-371.

To review
the safety
and
efficacy
data of
available
biosimilars
in
oncology.

Study
Results

Would
Use as
Level of
Evidence
Evidenc
to
Study
e (Use
Support a
Limitation
Melnyk
Change?
s
Framew
(Yes or
ork)
No)
Provide
Rationale.

23 RCTs.
8RCTs with
biosimilar
rituximab;
6 RCTs
with
biosimilar
bevacizuma
b; 9 RCTs
with
biosimilar

Systematic
review of RCTs
located from
search of
PubMed,
Embase, the
Cochrane
library,
ClinicalTrials.go
v, the ISI Web of
Science, and

The
existing
evidence
suggests
highly
comparable
efficacy and
safety
profiles
between
monocolon

b and
allows for
the use of
Ontruzuan
twhere
reference
trazumab
is
indicated.
Level 1:
Systemat
ic
review
and
metaanalysis.

Some
studies did
not include
OS and
PFS
outcomes.
Unable to
assess
publication
bias due to

Yes.
Evidence
suggests a
similar
efficacy
and safety
profile for
monoclonal
antibody
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Study
Purpose

Sample
(Character
istics of the
Sample:
Demograp
hics, etc.)

Methods

trastuzumab Chinese
.
databases
(CNKI,
Wanfang, and
SinoMed) from
inception to
December 31,
2018.
Keywords
included
biosimilar and
cancer.
Review
conducted
according to
PRISMA
statement.

Study
Results

al antibody
biosimilars
and the
reference
biologics in
oncological
drugs.

Would
Use as
Level of
Evidence
Evidenc
to
Study
e (Use
Support a
Limitation
Melnyk
Change?
s
Framew
(Yes or
ork)
No)
Provide
Rationale.
< 10
studies for
each
outcome.

biosimilar
s relative
to
reference
products.
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Note. AEs=adverse effects. ANAs=antineutrophil antibodies. CI=confidence interval. GCSF=granulocyte-colony stimulating factor. RCTs=randomized controlled trials.
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